GLOW Stack
GLOW peptide blend · GHK-Cu BPC-157 TB-500 stack · regenerative stack · glow peptide
Vendor name for a mixed vial, usually GHK-Cu + BPC-157 + TB-500 (7-mer). Common advertised SKU is 70 mg at 50/10/10. Not Argireline, not Matrixyl. Not a synergy RCT. Use the blend calculator.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Skin / cosmetic3/10
Named blend. GHK-Cu is the cosmetic story. BPC/TB-500 are not dermal drugs. Blend ≠ RCT.
- Injury & tissue3/10
Wolverine-adjacent marketing. TB-500 as sold is usually Ac-LKKTETQ, not Tβ4.
Compound card
- Class
- Vendor blend (typically GHK-Cu + BPC-157 + TB-500 7-mer)
- Formula
- GHK-Cu + BPC-157 + TB-500 7-mer (vendor mix)
- Status
- Not FDA-approved · research use
How it works
GLOW is a vendor nickname, not an INN. The usual research-chem cake is three lyophilized powders in one bottle: GHK-Cu (copper tripeptide), BPC-157 (15-mer GEPPPGKPADDAGLV), and TB-500 as sold (usually the actin-loop heptapeptide Ac-LKKTETQ, not full-length thymosin β4).
Complementary marketing is not a combination trial. There is no published human or animal study of the three together. GHK-Cu topical collagen papers (Pickart) do not transfer to a subcutaneous mix. BPC-157 remains a Zagreb-heavy animal file with independent PK in minutes, not the internet’s 4-hour half-life. Full-length Tβ4 cardiac and wound trials do not describe the 7-mer in this vial.
Not Argireline. Not Matrixyl. Those are topical cosmetics on other leaves. A 5:1:1 70 mg label is a common advertised split, not a monograph. Read each milligram on the COA, then use the blend calculator.
Source: PMID: 18492131 (GHK-Cu), PMID: 29936067 (BPC-157), PMID: 20435714 (TB-500)
No combination trial. BPC-157 is WADA S0 and FDA Category 2.
Every dosing table on this page is identity math for a common advertised 70 mg 5:1:1 cake, or community folklore from the separate leaves. It is not a protocol we are running on anyone. Active malignancy is a hard no on angiogenesis-signaling components. Competitive athletes: this bottle is not “research-use safe.”
No published human (or animal) trial has tested GHK-Cu + BPC-157 + TB-500 together. Component papers are not stack papers. TB-500 as sold is usually Ac-LKKTETQ, not full-length thymosin β4. Not Argireline. Not Matrixyl.
What is in the vial
GLOW is a catalog name, not an INN and not a trial arm. Most grey-market bottles that use the word are GHK-Cu-heavy three-peptide cakes. The math below is for a common advertised 70 mg 5:1:1 SKU. Your COA is the only ratio that matters.
GHK-Cu
50 mg in the advertised SKUGly-His-Lys copper complex. Majority of a typical 70 mg GLOW cake by mass, which is why PIP and copper cycling dominate the folklore.
Copper tripeptide. Topical collagen and gene-expression literature exists. That literature is not an injectable blend NDA.
BPC-157
10 mg in the advertised SKUGEPPPGKPADDAGLV. FDA Category 2. WADA S0. Human PK is not the internet’s “4-hour half-life.”
Synthetic 15-mer with a large Zagreb-heavy animal file. Not an FDA-approved healing drug.
TB-500
10 mg in the advertised SKUUsually Ac-LKKTETQ (CAS 885340-08-9), not 43-aa thymosin β4. Equine doping-control papers exist because sport was already using it.
Actin-binding 7-mer as sold. Do not launder full-length Tβ4 cardiac or wound trials onto this SKU.
Pre-blend math
Common advertised cake: 50 mg GHK-Cu + 10 mg TB-500 + 10 mg BPC-157. Example reconstitution 3 mL bacteriostatic water → 23.3 mg/mL total blend. Lots advertised as “GLOW” are not 70 mg and not 5:1:1. If the label disagrees with this table, throw the table out and use the blend calculator.
Concentration = 70 mg ÷ 3 mL. One U-100 unit = 0.01 mL ≈ 233 mcg total. Units = mL × 100.
Draw math for this advertised ratio
Arithmetic, not a dose recommendation10 units (0.10 mL) on a U-100 syringe is 0.1 mL. At 233 mcg/unit from a 70 mg / 3 mL cake, that is ~2.33 mg total blend. About 30 full draws before the vial is empty, ignoring priming waste.
How that draw compares to standalone folklore
“In range” here means the arithmetic of a 5:1:1 cake vs community standalone ranges. It is not efficacy, not synergy, and not a reason to prefer the blend.
| Component | This draw | Standalone folklore | Read |
|---|---|---|---|
| GHK-Cu | ~1.67 mg / 10 U | 1–2 mg daily is a common standalone research-chem range | Inside that folklore band, if the vial really is 5:1:1 |
| BPC-157 | ~0.33 mg / 10 U | 250–500 mcg daily is the usual community range | Inside that folklore band |
| TB-500 | ~0.33 mg / 10 U daily | Community logs often use 2–5 mg per injection, 2×/week | Far below that weekly-loading folklore. Convenience cake, not an injury-loading SKU. |
Separate vials
Separate vials are how you actually control each milligram. Do not pool three reconstitutions into one syringe because a blog said they are “compatible.” pH, preservative, and stability are not a published mix study. One syringe per compound unless a pharmacist compounded it that way.
| Peptide | Community range | Typical folklore frequency | Example recon math |
|---|---|---|---|
| BPC-157 | 250–500 mcg | Daily in community logs | 5 mg + 2 mL BAC → 2,500 mcg/mL. 500 mcg = 20 units (U-100). |
| TB-500 | 2–5 mg per injection (folklore) | Often 2×/week in community logs, not daily microdoses | 5 mg + 1 mL BAC → 5 mg/mL. 2.5 mg = 50 units (U-100). |
| GHK-Cu | 1–2 mg | Daily in community logs | 50 mg + 5 mL BAC → 10 mg/mL. 1 mg = 10 units (U-100). |
Cycle folklore
On/off calendars below are community structures, usually blamed on GHK-Cu copper handling. They are not studied durations for this mix.
| Approach | On | Off | Note |
|---|---|---|---|
| Short community cycle | 4–6 weeks | 2–4 weeks | Most common forum structure. Copper handling from GHK-Cu is the usual excuse for the off weeks, not a PK study of the blend. |
| Longer community cycle | 8–12 weeks | 4–8 weeks | Still folklore. Longer GHK-Cu exposure is more copper, not more evidence. |
| Skin-forward cake | About 4 weeks | 2–4 weeks | GHK-Cu mass dominates this SKU. That does not make topical Pickart papers injectable outcomes. |
Storage and reconstitution steps
| State | Storage | Note |
|---|---|---|
| Lyophilized | Cold, dry, dark. Many vendors say freezer. | Follow the COA. Moisture on a copper peptide cake is a discard. |
| Reconstituted | 2–8 °C. Do not freeze-thaw. | Use the shortest published reconstituted window among the three SKUs. Multi-peptide cakes are not 30-day magic. |
| Appearance | Clear, possible faint blue-green | Blue-green can be GHK-Cu. Particles, yellow-brown, or a sour smell: discard. |
- 01
Read the COA, not the nickname
Confirm each milligram on the label. GLOW and KLOW are vendor names. Ratios drift between lots.
- 02
Swab both stoppers
Alcohol on the blend vial and the bacteriostatic water. Let them dry.
- 03
Draw the water volume you actually chose
The tables on this page assume a common vendor water volume. If you add a different volume, rerun the blend calculator.
- 04
Aim at the glass wall
Inject water down the inside wall. Do not blast the cake. Foaming is wasted peptide, not a vibe.
- 05
Roll. Do not shake.
Gentle swirl until dissolved. GHK-Cu often tints the solution faint blue-green. That is copper, not contamination by itself. Cloudiness, clumps, or a brown shift is a discard.
- 06
Label date and fridge it
2–8 °C, dark. A multi-peptide cake is only as stable as the shortest-lived component. Vendor “30 days” claims are not a stability NDA.
- 07
Do the unit math before the first draw
Concentration = total mg ÷ water mL. Units on a U-100 syringe = mL × 100. Check it twice. Then check the COA again.
GLOW vs KLOW vs Wolverine
Ingredient count is not evidence quality. All three are vendor pairings. None has a combination RCT.
| Feature | Wolverine | GLOW | KLOW |
|---|---|---|---|
| In the bottle (typical vendor story) | BPC-157 + TB-500 7-mer | GHK-Cu + BPC-157 + TB-500 7-mer | GLOW four-way: adds KPV |
| Common advertised mass | Often 10–20 mg total | Often 70 mg (50/10/10) | Often 80 mg (50/10/10/10) |
| What the marketing is selling | Two-peptide recovery pair | Recovery pair plus copper-peptide skin story | GLOW plus an α-MSH fragment inflammation story |
| KPV | No | No | Yes (usually 10 mg) |
| GHK-Cu | No | Yes (usually the majority by mass) | Yes (usually the majority by mass) |
| Combination RCT | None | None | None |
| WADA | S0 via BPC-157 (and TB-500 as sold) | S0 via BPC-157 | S0 via BPC-157 |
| FDA compounding flag | Category 2 (BPC-157) | Category 2 (BPC-157) | Category 2 (BPC-157) |
- Wolverine · The two-peptide core without GHK-Cu. Same honesty problems, fewer milligrams of copper sting.
- KLOW · GLOW plus KPV. Four SKUs. Still no combo trial. Still not an IBD protocol.
- GHK-Cu · Read the copper-peptide leaf before you treat a blend as a skin drug.
- BPC-157 · Category 2, WADA S0, minutes-scale animal PK.
- TB-500 · 7-mer identity. Full Tβ4 trials stay on a different molecule.
Supply math
Planning counts assume the advertised cake, the example water volume, and one syringe per day. Round up for priming. This is inventory arithmetic.
| If you run | Vials (advertised size) | Why |
|---|---|---|
| 4 weeks daily | 1 × 70 mg | 28 draws. At 10 units/day from 3.0 mL you have ~30 draws before you are scraping the stopper. |
| 6–8 weeks daily | 2 × 70 mg | 42–56 draws. Second vial is margin, not a medical “course.” |
| 12 weeks daily | 3 × 70 mg | 84 draws. Round up for priming losses. Still not a trial duration. |
Background & History
GLOW showed up as a checkout nickname, not as a trial arm. Vendors needed a word for GHK-Cu plus the Wolverine pair in one lyophilized cake. The split that stuck in ads is 70 mg at 50/10/10 (GHK-Cu dominant). That ratio is convenience and skin-story mass, not a synergy finding. Argireline and Matrixyl are different cosmetics that sometimes get the same nickname in spa menus. This leaf is the research-chem three-peptide cake.
Research Use Cases
- ✓Identity: which three powders are in a bottle labeled GLOW
- ✓Blend math for a 70 mg 5:1:1 cake vs a COA that is not that split
- ✓Why TB-500 inside the cake is a daily microdose, not 2×/week loading folklore
- ✓Not a reason to skip the GHK-Cu, BPC-157, or TB-500 leaves
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Advertised 70 mg cake (example math) | 10 units = 0.10 mL ≈ 2.33 mg total from 3 mL | Once daily in community logs | At 5:1:1 that is ~1.67 mg GHK-Cu + ~0.33 mg BPC-157 + ~0.33 mg TB-500. COA first. Not a recommended dose. |
| Separate-vial folklore (not the cake) | GHK-Cu 1–2 mg daily · BPC-157 250–500 mcg daily · TB-500 2–5 mg 2×/week | Independent schedules | This is how standalone SKUs are logged. The pre-blend does not deliver TB-500 in that loading pattern. Separate syringes. Not a mix study. |
Administration
Timeline
Who it is for
Convenience vs dose control
LowThe cake is one reconstitution. You lose independent milligrams, especially TB-500. Separate vials if the job is actually one peptide.
Skin / cosmetic
LowGHK-Cu topical papers exist. A SubQ blend is not those papers. Not Argireline, not Matrixyl.
Soft-tissue recovery
LowWolverine-adjacent marketing. Component animal files plus forum logs. No stack trial. TB-500 in the cake is a daily microdose vs loading folklore.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| 70 mg advertised cake (50/10/10) | 3 mL BAC | 23.3 mg/mL total | 10 U = 0.10 mL ≈ 2.33 mg total (~1.67 / 0.33 / 0.33 mg). COA wins. |
Change vial size or water volume? Open the blend calculator.
Safety & Considerations
Three research SKUs in one bottle. No combination safety file. BPC-157 is FDA Category 2 and WADA S0. Angiogenesis signaling in the BPC and Tβ4 families is why active malignancy is a hard no. GHK-Cu is copper: Wilson’s disease and other copper-handling disorders are a hard no. Pregnancy and breastfeeding have no safety file. GHK-Cu is the usual post-injection pain. Confirm each mg on the COA. Quality risk scales with how many powders sat in the cake.
Regulatory & Legal Status
Vendor blend typically GHK-Cu + BPC-157 + TB-500. Contains BPC-157 (FDA Category 2). The named blend is not an approved product. PCAC Jul 2026 review is advisory, not a final rule
Competitive athletes subject to anti-doping controls should not use GLOW Stack.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- No published trial of GHK-Cu + BPC-157 + TB-500 together. Component papers are not stack papers.
- Do not treat full-length thymosin β4 papers as the 7-mer in the blend.
- Copper + multiple lyophilized peptides: confirm each mg on the COA. If the split is not 50/10/10, ignore the example tables.
Human evidence
None · no combination trial of the three
- No published human or animal trial of GHK-Cu + BPC-157 + TB-500 together.
- Component papers stay on their own leaves. A mixed cake does not inherit those results.
- A 70 mg 5:1:1 label is a common advertised split, not a monograph.
User reports
What people report anyway
Injection-site sting from GHK-Cu, sometimes a copper-blue tint. Recovery and skin stories are anecdote stacked on three separate literatures.
Verdict
GLOW on vendor menus is usually GHK-Cu + BPC-157 + TB-500, not Argireline + Matrixyl. A 70 mg 5:1:1 label is a common advertised split, not a monograph. A mixed vial is not a synergy trial. Use the blend calculator.
Interactions & Contraindications
No mix DDI package. BPC-157 is WADA S0 and FDA Category 2. Angiogenesis signaling: active malignancy is a hard no. GHK-Cu is copper (Wilson’s). Confirm each mg on the COA.
Synergies & Common Stacks
Wolverine is the two-peptide core. GLOW adds GHK-Cu. Same honesty problems, extra copper sting.
KLOW is this cake plus KPV. Four SKUs. Still no combo trial.
GLOW Stack vs. KLOW Stack
Canonical comparison: GLOW Stack vs KLOW Stack
| Attribute | GLOW Stack | KLOW Stack |
|---|---|---|
| Components | GHK-Cu + BPC-157 + TB-500 7-mer | GLOW four-way: adds KPV |
| Common advertised mass | 70 mg at 50/10/10 | 80 mg at 50/10/10/10 |
| GHK-Cu share | ~71% of a 5:1:1 cake | 62.5% of a 50/10/10/10 cake |
| KPV | No | Yes (usually 10 mg) |
| Combo trial | None | None |
| WADA / FDA flag | S0 + Category 2 via BPC-157 | Same inheritance |
Verdict: KLOW is GLOW plus KPV. If you cannot name a KPV-specific job, the extra powder is a checkout nickname. Neither mix is a synergy RCT.
GLOW Stack vs. Wolverine Stack
Canonical comparison: GLOW Stack vs Wolverine Stack
| Attribute | GLOW Stack | Wolverine Stack |
|---|---|---|
| Components | GHK-Cu + BPC-157 + TB-500 | BPC-157 + TB-500 only |
| Copper peptide | Yes. Usual PIP source. | No |
| Job in the ads | Recovery plus skin/ECM story | Two-peptide recovery pair |
| Evidence | Component preclinical; no blend RCT | Same class of problem, fewer SKUs |
Verdict: Wolverine is the core pair. GLOW adds GHK-Cu mass and sting. Ingredient count is not evidence quality.
Frequently Asked Questions
What is the GLOW stack?▼
Has anyone tested the three peptides together?▼
What is the 70 mg 5:1:1 vial?▼
Why is TB-500 so low in the pre-blend?▼
GLOW vs Wolverine vs KLOW?▼
Can I mix separate vials in one syringe?▼
Why does the injection burn?▼
Is GLOW allowed in tested sport?▼
Is this the same as Argireline or Matrixyl?▼
How do I dose a vial that is not 70 mg 5:1:1?▼
References
- Pickart L, Margolina A. “GHK peptide as a natural modulator of multiple cellular pathways in skin biology.” Biomed Res Int (2015). PMID: 26236730
- Pickart L. “The human tripeptide GHK-Cu in prevention and treatment of skin aging.” Int J Cosmet Sci (2012). PMID: 22486774
- Sikiric P, et al. “Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing.” Curr Pharm Des (2018). PMID: 29936067
- He L, et al. “Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.” Front Pharmacol (2022). PMID: 36588717
- Ho EN, et al. “Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by LC-MS.” Drug Test Anal (2012). PMID: 23084823
📚 Related Articles
Get GLOW Stack from our recommended source - independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review